Released July 02, 2020 | India
en
India's leading vaccine-maker, Bharat Biotech Limited, is set to start human clinical trials for its COVID-19 vaccine candidate, Covaxin, which is India's first indigenously-developed vaccine against the coronavirus.
Covaxin was developed by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). Drug Controller General of India (DCGI) on Monday granted Bharat Biotech approval to undertake the clinical trials, which are scheduled to start across India in July.
"The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad," the company said in a media release.
Industrial Info is tracking 58 COVID-19-related projects, worth $357 million, in India. Click here for a list and see map below.
Covaxin was developed by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). Drug Controller General of India (DCGI) on Monday granted Bharat Biotech approval to undertake the clinical trials, which are scheduled to start across India in July.
"The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad," the company said in a media release.
Industrial Info is tracking 58 COVID-19-related projects, worth $357 million, in India. Click here for a list and see map below.
